Form 4 for ORKA Oruka Therapeutics, Inc.
Accepted 2026-03-17 00:00:00 ET · period of report 2026-03-16 · accession 0000907654-26-000033 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-17 | 2026-03-16 | ORKA | Klein Lawrence Otto | CEO, Dir | S - Sale | $41.30 | -1,729 | 927.3K | -0.2% | -$71.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-16 | S | D | 1,729 | $41.30 | 927,309 | D | — | — |